Systemic scleroderma

Chemomab Therapeutics Hosting Key Opinion Leader Webinar on Systemic Sclerosis

Retrieved on: 
星期二, 十月 26, 2021
Woman, Fibrosis, KOL, TEL, MD, Research, Master of Science, Inflammation, University, Disease, Industry, Knowledge, Survival, Scleroderma, Cirrhosis, Caregiver, Patient, Private Securities Litigation Reform Act, SEC, Communication, Nature, Systemic scleroderma, Primary sclerosing cholangitis, Forward-looking statement, Marketing, Risk, National, National Institutes of Health, Skin, PSC, Baozou Big News Events, Joint, CMMB, Therapy, News, Q&A, Frederick, CCL24, Pharmaceutical industry, Medical device

TEL AVIV, Israel, Oct. 26, 2021 /PRNewswire/ --Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that it will host a key opinion leader (KOL) live webinar featuring systemic sclerosis (SSc) expert Dr. Dinesh Khanna on Wednesday, November 3, 2021, at 10:00 am Eastern Time.

Key Points: 
  • TEL AVIV, Israel, Oct. 26, 2021 /PRNewswire/ --Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that it will host a key opinion leader (KOL) live webinar featuring systemic sclerosis (SSc) expert Dr. Dinesh Khanna on Wednesday, November 3, 2021, at 10:00 am Eastern Time.
  • CM-101 is a first-in-class monoclonal antibody targeting CCL24, a key regulator of fibrotic and inflammatory processes.
  • A replay of the KOL webinar will also be available at the News & Events section of Chemomab's website.
  • Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need.

Medical Marijuana Cannabidiol Pipeline Insight Report 2021: Focus on 25 Companies & 50 Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
星期一, 十月 18, 2021
Tobacco, Retail, Alternative Medicine, Health, Olive oil, EB, Diabetes, CB2, Pharma, Endothelium, Obstructive sleep apnea, TS, Agitation, Dermatomyositis, PEA, Cancer, Depression, Cannabinoid, INMED, Pain, Red, Spasticity, Epidermolysis bullosa, Systemic scleroderma, Health, Cystic fibrosis, Medical cannabis, THC, Therapy, Nausea, Multiple sclerosis, Disease, Neuromuscular junction disease, Fibroblast, Inflammation, Patient, Tourette syndrome, Dementia, Appetite, Chronic pain, Cannabinol, Arthritis, Hidradenitis suppurativa, Swelling, Entourage effect, University College London, Mergers and acquisitions, Safety, Dronabinol, Anxiety, Research, Muscle, III, Kindler syndrome, Timeline of cannabis laws in the United States, OSA, UCL, Dietary supplement, Drug, Pharmaceutical industry

"Medical Marijuana - Cannabidiol - Pipeline Insight, 2021" report provides comprehensive insights for about 25+ companies and 50+ pipeline drugs in Medical Marijuana - Cannabidiol pipeline landscape.

Key Points: 
  • "Medical Marijuana - Cannabidiol - Pipeline Insight, 2021" report provides comprehensive insights for about 25+ companies and 50+ pipeline drugs in Medical Marijuana - Cannabidiol pipeline landscape.
  • Currently, the two main cannabinoids from the marijuana plant that are of medical interest are THC and CBD.
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medical Marijuana - Cannabidiol?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Medical Marijuana - Cannabidiol therapeutics?

Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis

Retrieved on: 
星期一, 十月 18, 2021
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Myofibroblast, Interstitial lung disease, Matrix, HIV disease progression rates, LPA, Systemic scleroderma, Lung, LinkedIn, Achievement, Autotaxin, Liver, Fibrosis, Mortality, Disease, Enzyme, FDA, Institute of Liver and Biliary Sciences, Scleroderma, NASH, Clinical trial, Patient, Aggregation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neurodegeneration, Food, CEO, IPF, Safety, CYP450, Therapy, Pharmacokinetics, Kidney, Pharmaceutical industry

Blade continues to make progress advancing the clinical development program for cudetaxestat, said Wendye Robbins, M.D., president and CEO of Blade.

Key Points: 
  • Blade continues to make progress advancing the clinical development program for cudetaxestat, said Wendye Robbins, M.D., president and CEO of Blade.
  • We are encouraged by the recent achievement of several development milestones for cudetaxestat and look forward to executing on the planned path ahead.
  • The study remains on track and is expected to be completed in the fourth quarter of 2021.
  • In addition, autotaxin levels correlate with fibrosis severity in various liver diseases (e.g., nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NASH)).

Blade Therapeutics Announces FDA Orphan Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis

Retrieved on: 
星期四, 十月 14, 2021
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Myofibroblast, Matrix, HIV disease progression rates, MBA, Diagnosis, LPA, Systemic scleroderma, Lung, LinkedIn, Liver, Autotaxin, Fibrosis, Trial of the century, Doctor of Pharmacy, Mortality, Disease, FDA, Institute of Liver and Biliary Sciences, Scleroderma, Joint, Skin, NASH, Clinical trial, Patient, Aggregation, Neurodegeneration, IPF, Safety, Therapy, Pharmacokinetics, Blade, Kidney, Pharmaceutical industry

Blade Therapeutics, Inc. (Blade or the company), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that the FDA has granted orphan drug designation for cudetaxestat for the potential treatment of systemic sclerosis (SSc).

Key Points: 
  • Blade Therapeutics, Inc. (Blade or the company), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that the FDA has granted orphan drug designation for cudetaxestat for the potential treatment of systemic sclerosis (SSc).
  • There are limited options and high medical need for patients suffering from systemic sclerosis, said Daven Mody, PharmD, MBA, vice president of regulatory affairs with Blade.
  • Cudetaxestat received its first orphan drug designation in February 2021 for the potential treatment of IPF.
  • Cudetaxestat has been granted orphan drug designations in the treatment of IPF and SSc.

Ashley Barron's Debut Album Challenges The Male-Dominated Country Genre

Retrieved on: 
星期二, 九月 28, 2021
Beer, Music, Instagram, Systemic scleroderma, Collection, Multimedia, Billboard, Heart, Writing, Life, Barron, Facebook, Ashley

NASHVILLE, Tenn., Sept. 28, 2021 /PRNewswire/ -- Country music artist, Ashley Barron, released her self-titled debut album on September 24th.

Key Points: 
  • NASHVILLE, Tenn., Sept. 28, 2021 /PRNewswire/ -- Country music artist, Ashley Barron, released her self-titled debut album on September 24th.
  • Her first radio single, "Beer in a Bar", received critical acclaim and topped the Billboard country indicator chart at #37.
  • In a time where country music needs even more strong females in a male-dominated genre, Ashley Barron's upbeat, compassionate, outlaw approach will help break through that stronghold.
  • To learn more about Ashley Barron, visit her website at www.ashleybarronofficial.com or follow her on Instagram and Facebook at @ashleybarronofficial.

iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
星期一, 九月 27, 2021
Therapy, Income, Systemic scleroderma, Conference, Catalog, Hotel manager, Senior management, Growth, Service, IND, Calendar, Glycosylation, Investment, Tumor microenvironment, SEC, Protein, Vaccine, Compliance, Investor, Board of directors, Webcast, Hydroponics, CEO, Disease, NYSE American, Maintenance, History, Biomanufacturing, NYSE, Bioprocess, Infection, Cancer, Partnership, Annual report, CGMP, Sale, Â, Marketing, Chief executive officer, Company, Risk, Severe acute respiratory syndrome coronavirus 2, Drug discovery, Fibrosis, Contract, Time, GLOBE, G&A, CDMO, Cytokine, Board, Fraunhofer Society, COVID-19, Antigen, Research, Lectin, Fine chemical, Pharmaceutical industry, Video game

BRYAN, Texas, Sept. 27, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced its financial results for the fiscal fourth quarter and year ended June 30, 2021.

Key Points: 
  • Fiscal Fourth Quarter and Recent Business Developments:
    In June 2021, iBio established a new drug discovery team based in San Diego.
  • Fiscal Fourth Quarter and Recent Corporate Developments:
    Throughout fiscal 2021 and FY22 year-to-date, iBio increased its bench strength and enhanced its leadership team to support its growth strategy.
  • R&D and G&A expenses for the fourth quarter and full fiscal year 2021 increased significantly over the comparable periods in fiscal year 2020.
  • G&A expense was up $10.6 million to $22.0 million in fiscal 2021, rising $3.5 million to $6.6 million in the fourth quarter.

Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer

Retrieved on: 
星期四, 九月 2, 2021
Company, Sustainability Accounting Standards Board, Private Securities Litigation Reform Act, University, CMMB, Cirrhosis, Fibrosis, Microbiome, Therapy, Growth, Nature, Acquisition, Communication, CSO, Brown University, SEC, Board of directors, Smith, Kline & French, Research, CCL24, Partner, Doctor of Philosophy, Risk, TEL, PSC, Systemic scleroderma, Marketing, Oxford, Forward-looking statement, Inflammation, Biotechnology, Board, Physics, Genomics, Patient, CEO, History, Primary sclerosing cholangitis, Compugen (Israeli company), Health, General partnership, Management, Fine chemical, Pharmaceutical industry

(Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for inflammatory and fibrotic diseases with high unmet need, today announced it has appointed Dale R. Pfost, PhD, as Chief Executive Officer (CEO).

Key Points: 
  • (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for inflammatory and fibrotic diseases with high unmet need, today announced it has appointed Dale R. Pfost, PhD, as Chief Executive Officer (CEO).
  • Dr. Pfost is expected to join the Company's Board of Directors and subsequently become the company's Chairman in 2022.
  • "The Board and I welcome Dale and thank Adi for her tremendous contributions as founding chief executive of Chemomab," said Stephen Squinto, PhD, Chairman of the Board at Chemomab and an Executive Partner at OrbiMed.
  • Dr. Pfost has served as CEO of six biotechnology companies, threeof whichbecame publicly traded with valuations exceeding two billion dollars.

Chemomab to Participate in Upcoming September Investor Conferences

Retrieved on: 
星期三, 九月 1, 2021
Private Securities Litigation Reform Act, Fibrosis, Therapy, Nature, Communication, SEC, CCL24, Research, Risk, PSC, Systemic scleroderma, Marketing, Forward-looking statement, Inflammation, Patient, News, Scleroderma, Online shopping, Pharmaceutical industry

The presentations and archived webcasts will also be accessible in the News and Events section of the Chemomab website.

Key Points: 
  • The presentations and archived webcasts will also be accessible in the News and Events section of the Chemomab website.
  • Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need.
  • Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101 , a monoclonal antibody designed to bind and block CCL24 activity.
  • Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements.

Global Scleroderma Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
星期三, 七月 21, 2021
Health, Clinical trials, Health sciences, Health, Life sciences, Drug discovery, Clinical research, Pharmaceutical industry, Autoimmune diseases, Mucinoses, Scleroderma, Clinical trial, Systemic scleroderma

The "Global Scleroderma Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Scleroderma Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Scleroderma Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Scleroderma market.
  • It covers emerging therapies for Scleroderma in active clinical development stages including early and late stage clinical trials.
  • The report provides Scleroderma pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Systemic Sclerosis (Scleroderma) Epidemiology Forecast to 2030: Focus on US, France, Germany, Italy, Spain, UK, and Japan - ResearchAndMarkets.com

Retrieved on: 
星期四, 六月 10, 2021
Biotechnology, Pharmaceutical, Health, Organ systems, Autoimmune diseases, Mucinoses, Medicine, Anatomy, Rare diseases, Systemic scleroderma, Scleroderma, Sclerosis

The "Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of SSc.
  • Women accounted for more diagnosed prevalent cases of SSc than men in the 7MM and it predominantly affects older adults.
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of SSc segmented by sex and age (ages 18 years).